LP
MRTX

LMR Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

LMR Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,627
Closed -$792K – 1516
2022
Q1 		$792K Sell
9,627
-8,500
-47% -$869K 0.01% 891
2021
Q4 		$2.66M Buy
18,127
+16,101
+795% +$2.5M 0.03% 396
2021
Q3 		$358K Sell
2,026
-8,884
-81% -$1.43M ﹤0.01% 855
2021
Q2 		$1.76M Buy
+10,910
New +$1.75M 0.03% 399
2017
Q3 		– Sell
-64,760
Closed -$236K – 588
2017
Q2 		$236K Buy
+64,760
New +$248K 0.01% 505

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

LMR Partners's MRTX Position: Q2 2022 in Review

LMR Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 9,627 shares — an estimated $792K sold.

LMR Partners first reported a position in MRTX in Q2 2017 and held it in 5 quarters. The position peaked at $2.66M in Q4 2021. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

  • LMR Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • LMR Partners sold 9,627 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $792K.
  • LMR Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2017 and held it in 5 quarters.
  • LMR Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $2.66M in Q4 2021.
  • 230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on LMR Partners's 13F filing for Q2 2022, filed 15 Aug 2022.